If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Andrea Ferrari is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles
Pediatrics Medicine & Life Sciences
Sarcoma Medicine & Life Sciences
Rhabdomyosarcoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Synovial Sarcoma Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1997 2019

  • 7627 Citations
  • 47 h-Index
  • 326 Article
  • 8 Review article
  • 1 Chapter
  • 1 Comment/debate
1 Citation (Scopus)

MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort

IMI Study Group, GEM Study Group & M-SKIP Study Group, May 1 2019, In : The Lancet Child and Adolescent Health. 3, 5, p. 332-342 11 p.

Research output: Contribution to journalArticle

Receptor, Melanocortin, Type 1
Melanoma
Genes
Odds Ratio
Serbia

Prognostic role of pleural effusion or ascites in localized rhabdomyosarcoma

Di Carlo, D., Ferrari, A., Toffolutti, T., Milano, G. M., Manzitti, C., Ruggiero, A., Dall'Igna, P., Melchionda, F., Zanetti, I., Scarzello, G. & Bisogno, G., Nov 2019, In : Pediatric Blood and Cancer. 66, 11, p. e27932

Research output: Contribution to journalArticle

Rhabdomyosarcoma
Pleural Effusion
Ascites
Confidence Intervals
Disease-Free Survival

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

European paediatric Soft tissue sarcoma Study Group, Aug 2018, In : The Lancet. Oncology. 19, 8, p. 1061-1071 11 p.

Research output: Contribution to journalArticle

Rhabdomyosarcoma
Doxorubicin
Drug Therapy
Intravenous Infusions
Intravenous Injections

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Group, E. P. S. T. S. S., Bisogno, G., Jenney, M., Bergeron, C., Gallego Melcón, S., Ferrari, A., Oberlin, O., Carli, M., Stevens, M., Kelsey, A., De Paoli, A., Gaze, M. N., Martelli, H., Devalck, C., Merks, J. H., Ben-Arush, M., Glosli, H., Chisholm, J., Orbach, D., Minard-Colin, V. & 1 others, De Salvo, G. L., Aug 1 2018, In : The Lancet Oncology. 19, 8, p. 1061-1071 11 p.

Research output: Contribution to journalArticle

Rhabdomyosarcoma
Doxorubicin
Drug Therapy
Intravenous Infusions
Intravenous Injections

Alveolar soft part sarcoma in children and adolescents: The European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005)

Brennan, B., Zanetti, I., Orbach, D., Gallego, S., Francotte, N., Van Noesel, M., Kelsey, A., Casanova, M., De Salvo, G. L., Bisogno, G. & Ferrari, A., Apr 2018, In : Pediatric Blood and Cancer. 65, 4

Research output: Contribution to journalArticle

Alveolar Soft Part Sarcoma
Sarcoma
Prospective Studies
Pediatrics
Rhabdomyosarcoma